Brief: Solid Biosciences Says Ends Q1 With About $185.5 Mln In Cash
May 11 (Reuters) - Solid Biosciences Inc SLDB.O :
* SOLID BIOSCIENCES INC SAYS ENDS Q1 WITH ABOUT $185.5
MILLION IN
CASH AND INVESTMENTS; ANTICIPATED CASH RUNWAY INTO 2025
* SOLID BIOSCIENCES INC SAYS NO COLLABORATION REVENUES FOR
Q1 OF
2023
* SOLID BIOSCIENCES INC SAYS NET LOSS FOR Q1 OF 2023 WAS
$30.1
MILLION
Source text for Eikon: ID:nGNX6Lq190
Further company coverage: SLDB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Solid Biosciences
See all newsSolid Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Solid Biosciences Inc expected to post a loss of 48 cents a share - Earnings Preview
Solid Biosciences Q2 net loss widens on higher R&D costs
Marketing Agreement To Advance Gene Therapy Delivery And Analytics
Solid Biosciences Q1 net loss widens on higher R&D costs